Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-05-24
2005-05-24
Fredman, Jeffrey (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S005000, C435S091100, C435S091200, C536S023100, C536S024500, C514S04400A
Reexamination Certificate
active
06897016
ABSTRACT:
Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5126260 (1992-06-01), Tuan et al.
patent: 5225337 (1993-07-01), Robertson
patent: 5389514 (1995-02-01), Taylor
patent: 5498531 (1996-03-01), Jarrell
patent: 5641673 (1997-06-01), Haseloff et al.
patent: 5667969 (1997-09-01), Sullenger
patent: 5869254 (1999-02-01), Sullenger
patent: 9001731 (1990-05-01), None
patent: 8804300 (1988-06-01), None
patent: 9207065 (1992-08-01), None
patent: 9213089 (1992-08-01), None
patent: 9213090 (1992-08-01), None
patent: WO 9213090 (1992-08-01), None
patent: 9300833 (1993-05-01), None
Weber et al, “Antiviral properties of a dominant negative mutant of the herpessimplex virus type 1 regulatory protein (ICPO)”, J. Gen. Virol. 73:2955-2961.*
Rossi, “Controlled, targeted, intracellular expression of ribozymes: progress and problems”, Trends in Biotechnology 13(8):301-305.*
Komatsu et al., “Cross-litigation and Exchange Reactions Catalyzed by Hairpin Ribozymes,”Nucleic Acids Res.21;185-190 (1993)
Friedman et al., “Expression of a Truncated Viral Trans-activator Selectively Impede Lytic Infection by its Cognate Virus”Nature335, p. 452 (1988).
Flanegan and Cech, “Tetrahymena Ribozyme Catalyzes Trans-splicing of Model Oligoribonucleotide Substrates,”J. Cell. Biochem,12D, 4 Apr., New York, p. 28.
Cech, “The Chemistry of Self-splicing RNA and RNA Enzymes”Science236, 1532-1539 (1987).
Sullenger and Cech, “Ribozyme-mediated Repair of Defective mRNA by Targeted Trans-splicing”Nature371, 619-622 (1994).
Guthrie, “Messenger RNA Splicing in Yeast: Clues to Why the Spliceosome Is a Ribonucleoprotein”Science253, p. 257 (1991).
Kim et al., “Three-dimensional Model of the Active Site of the Self-splicing Rrna Precursor of Tetrahymena”Proc. Nat. Acad, of Sci, USA84, p. 8788 (1987).
Haseloff et al., “Simple RNA Enzymes with a New and Highly Specific Endoribonuclease Activities”Nature234, p. 585 (1988).
Cech, “Ribozymes and their Medical Implications”JAMA260, p. 3030 (1988).
Jefferies et al., “A Catalytic 13-mer Ribozyme”Nucl. Acid Res.17, p. 1371 (1989).
Rossi et al., Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and ProblemsAids Res. and Human Retroviruses8, p. 183 (1992).
Hampel and Tritz, “RNA Catalytic Properties of the Minimum (-) sTRSV Sequence”Biochem,28, p. 4929 (1989).
Hampel et al., “ ‘Hairpin’ Catalytic RNA Model:Evidence for Helices and Sequence Requirement for Substrate RNA”Nucl. Acid. Res,18, p. 299 (1990).
Perrotta and Been, “Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis—Virus RNA Sequence”Biochem.31, p. 16 (1992).
Guerrier-Takada et al., “The RNA Moiety of Ribonuclease P is the Catalytic Subunit of the Enzyme”Cell35, p. 849 (1983).
Inoue et al., “Intermolecular Exon Ligation of the Rrna Precursor of Tetrahymena: Oligonucleotides Can Function as 5′Exons”Cell43, p. 849 (1983).
Bruzik and Maniatis, “Splicing Leader RNAs From Lower Eukaryotes are Trans-spliced in Mammalian Cells”Nature360, p. 692 (1992).
Cech et al., “In Vitro Splicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence”Cell27, p. 487 (1981).
Kruger et al., “Self-splicing RNA: Autoexcision and Autocyclization of the Ribosomal RNA Intervening Sequence of Tetrahymena”Cell31, p. 147 (1982).
Rossi et al., “Controlled Targeted Intracellular Expression of Ribozymes: Progress and Problems”TIBtechvol. 13, (1995).
U.S. Appl. No. 08/152,450, filed Nov. 12, 1993, Sullenger et al.
Been and Cech, “One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self-Splicing, Trans-Splicing and RNA Enzyme Activity,”Cell47:207-216 (1986).
Cech, “Ribozyme Engineering,”Current Opinion in Structural Biology2:605-609 (1992).
Dzierzak et al., “Lineage-specific expression of a human β-globin gene in murine bone marrow transplant receipients reconstituted with retrovirus-transduced stem cells,”Nature,331, 35-41 (1989).
Inoue et al., “Intermolecular Exon Ligation of the rRNA Precursor of Tetrahymena: Oligonucleotides Can Function as a 5′ Exons,”Cell43:431-437 (1985).
Konarska et al., “TransSplicing of mRNA Precursors in Vitro,”Cell42:165-171 (1985).
Malim, et al., “functional Dissection of the HIV-1 Rev Trans-Activator—Derivation of a Trans-Dominant Repressor of Rev Function,”Cell,58, 205-214 (1989).
Morgan and Anderson, “Human Gene Therapy,”Annu. Rev. Biochem.62:191-217 (1993).
Murphy and Cech, “Alteration of Substrate Specificity for the Endoribonucleolytic Cleavage of RNA by theTetrahymenaRibozyme,”Proc. Natl. Acad. Sci. USA86:9218-9222 (1989).
Price and Cech, “Coupling ofTetrahymenaRibosomal RNA Splicing to β-Galactosidase Expression inEscherichia coli,” Science228:719-722 (1985).
Price, et al., “Determinants of the 3′ splice site for self-splicing of theTetrahymenapre-rRNA,”Genes and Development,2, 1439-1447 (1988).
Sarver et al., “Ribozymes as Potential Anti-HIV-1 Therapeutic Agents”Science247:1222-1225 (1990).
Smith et al., “Development of a lacZ Marked WEHI-3B D+Murine Leukemic Cell Line as an In-Vivo Model fo Actue Non-Lymphocytic Leukemia,”Leukemia,7 310-317 (1993).
Solnick, “TransSplicing of mRNA Precursors,”Cell42:157-164 (1985).
Sullenger et al., “Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication,”Cell63:601-608 (1990).
Trono et al., “HIV-1 Gag Mutants Can Dominantly Interfere with e Replication of the Wild-Type Virus,”Cell,59, 113-120 (1989).
Tsuchihashi et al., “Protein Enhancement of Hammerhead Ribozyme Catalysis,”Science262:99-102 (1993).
van der Veen et al., “Excised Group II Introns in Yeast Mitochondria are Lariats and Can Be Formed by Self-splicing In Vitro,”Cell44:225-234 (1986).
Waring et al., “The Tetrahymena rRNA Intron Self-Splices inE. coli: In Vivo Evidence for the Importance of Key Base-Paired Regions of RNA for RNA Enzyme Function,”Cell40:371-380 (1985).
Weber et al., “Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0,”Journal of General Virology73:2955-2961 (1992).
Zaug and Cech, “The Intervening Sequence RNA ofTetrahymenaIs a Enzyme,”Science231:470-475 (1986).
Zaug et al., “TheTetrahymenaRibozyme Acts Like an RNA Restriction Endonuclease,”Nature324:429-433 (1986).
Cech Thomas R.
Sullenger Bruce A.
Fredman Jeffrey
McDonnell & Boehnen Hulbert & Berghoff
The Regents of the University of Colorado
LandOfFree
Alteration of sequence of a target molecule does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alteration of sequence of a target molecule, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of sequence of a target molecule will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448330